Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany.
Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany; Lehrstuhl für Neurogenetik, Technische Universität München, Munich, Germany; Munich Cluster for Systems Neurology, SyNergy, Munich, Germany.
Parkinsonism Relat Disord. 2022 Sep;102:131-140. doi: 10.1016/j.parkreldis.2022.08.019. Epub 2022 Aug 28.
Animal and human brain-imaging studies have suggested a role for neurodevelopmental abnormalities in the pathophysiology of dystonia. Variants in neurodevelopmental genes have also been sporadically implicated, although no systematic investigation has been undertaken before the more widespread availability of genome-wide sequencing techniques. Here, we review findings from recent whole-exome and whole-genome sequencing approaches in individuals with dystonic conditions, indicating that more than 50% of molecularly diagnosed cases may have variants in neurodevelopmental disorder-associated genes. We describe how genomic sequencing has contributed to phenotypic expansions of several known hereditary forms of dystonia to include classical neurodevelopmental features. Moreover, we demonstrate that many of the newly reported monogenic neurodevelopmental disorders can manifest with prominent dystonic presentations, including isolated generalized dystonia, paroxysmal dystonia, and dopa-responsive dystonia-parkinsonism. Considering the published evidence, we argue that the clinical feature dystonia might be regarded as an expression of developmental brain dysfunction, a status referring to the common etiological basis of many neurodevelopmental disease traits. Finally, we provide a view into clinical implications, including the necessity to integrate the interrogation of neurodevelopmental disorder-associated genes into the molecular analysis process of patients with dystonia. Recognizing the relationship between dystonia and neurodevelopmental disorders is important to improve patient counseling and management and develop novel therapeutic strategies.
动物和人类的大脑成像研究表明,神经发育异常在肌张力障碍的病理生理学中起作用。神经发育基因的变异也时有报道,尽管在全基因组测序技术广泛应用之前,尚未进行系统的研究。在这里,我们回顾了最近在肌张力障碍患者中进行的全外显子组和全基因组测序方法的研究结果,表明超过 50%的分子诊断病例可能存在神经发育障碍相关基因的变异。我们描述了基因组测序如何有助于将几种已知遗传性肌张力障碍形式的表型扩展,包括经典的神经发育特征。此外,我们证明许多新报道的单基因神经发育障碍也可以表现出明显的肌张力障碍表现,包括孤立性全身性肌张力障碍、发作性肌张力障碍和多巴反应性肌张力障碍-帕金森病。考虑到已发表的证据,我们认为临床特征肌张力障碍可能被视为发育性脑功能障碍的表现,这一状态指的是许多神经发育疾病特征的共同病因基础。最后,我们提供了一些临床意义的观点,包括有必要将神经发育障碍相关基因的检测纳入肌张力障碍患者的分子分析过程。认识到肌张力障碍与神经发育障碍之间的关系对于改善患者的咨询和管理以及开发新的治疗策略非常重要。